In the EU they only have the non-substitutable pathway, in the US we have no regs at all yet.
So it makes no sense to say they are not interested in the bioequivalent pathway.
Certainly it would seam in Sandoz's ballpark to have substitutable biologics.
Also, the MNTA tech is useful even for non-equivalent versions. As an example, there are generic Lovenox's on the market now that are clearly not the same, thus will never command near the price. Also, the dev pathway will be cleaner and faster with the MNTA tech.
Regardless, I could care less about a NVS buyout. All these "buyout" posts are just Y!MB junk.